About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

WITHDRAWNNCT03722381

Evaluation of Amlodipine Pharmacokinetics in Patients Receiving Hi Flux Hemodialysis

The current study will evaluate the plasma pharmacokinetics of amlodipine in a cohort of 8 adult volunteers who are receiving regular hemodialysis treatment (HD) 3 days a week for 4 hours each day and...

Lead sponsor: University of Michigan•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Sponsors

Lead Sponsor

University of Michigan

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. 18 years of age or older
•2. Indwelling tunneled catheter, AVF, AVG that is currently used for hemodialysis
•3. Receiving in-center hemodialysis 3 days a week for 3-4.5 hours each treatment
•4. Taking a total daily dose of 5-10 mg of amlodipine as prescribed by their physician
•5. Hemoglobin ≥ 9.5 g/dL on most recent laboratory assessment prior to study

Exclusion Criteria

•1. Any condition that would not allow for arm BP to be taken
•2. Hemoglobin \< 9.5 g/dL on most recent lab prior to study
•3. Patient is on a CYP3A4 inhibitor (most common in HD population include: amiodarone, clarithromycin, cyclosporine, diltiazem, erythromycin, fluconazole, fluoxetine, fluvoxamine, nefazodone, tamoxifen, verapamil, and grapefruit juice).

Related studies

RECRUITINGPhase 4

Investigating the Pharmacokinetics of Tafenoquine in Healthy Papua New Guinean Children

NCT07052162 · Pharmacokinetics of Tafenoquine

The Effectiveness of Education in Diabetic Hemodialysis Patients

NCT07462741 · Hemodialysis Patient, Diabetes Foot Care

PK/PD of Caspofungin in Children Severe Infection

NCT04961593 · Pharmacokinetics, Infection, Fungal

Technology Assisted Collaborative Care Intervention to Improve Patient-centered Outcomes in Dialysis Patients

NCT06978127 · Chronic Kidney Disease Requiring Hemodialysis

Pivotal Study of the Velocity™ pAVF System

NCT07153939 · Chronic Kidney Disease, Hemodialysis Access, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 31, 2020Terms

Trial snapshot

StatusWITHDRAWN

Phase—

Enrollment—

Start dateJan 2020

Last updatedJan 31, 2020

Condition

Hemodialysis Pharmacokinetics

Locations shown

University of Michigan Dialysis

Ann Arbor, Michigan

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 31, 2020Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions